Fludarabine: a review

Area of Science:

• Oncology
• Pharmacology

Background:

• Fludarabine is a novel fluorinated adenine analog.
• Existing nucleoside analogs include cytarabine (antileukemic) and vidarabine (antiviral).
• Fludarabine exhibits resistance to adenosine deaminase deactivation, unlike vidarabine.

Purpose of the Study:

• To evaluate the efficacy and toxicity of fludarabine in various tumor types.
• To determine the therapeutic potential of fludarabine in different leukemias.
• To compare fludarabine's tolerability in acute leukemias versus chronic lymphocytic leukemia (CLL).

Main Methods:

• Phase I and II clinical trials were conducted.
• Efficacy and toxicity data were collected across multiple tumor types.
• Dose-response and tolerability were assessed for different leukemias.

Main Results:

• Fludarabine demonstrated potential efficacy in acute lymphocytic leukemia, acute nonlymphocytic leukemia, and CLL.
• Effective doses for acute leukemias exceeded the maximum tolerated dose, causing severe toxicity.
• Doses for satisfactory response in CLL were within tolerated limits.
• Observed toxicities include hematologic issues, neurotoxicity, and organ abnormalities.

Conclusions:

• Fludarabine is a potentially effective agent for CLL at well-tolerated doses.
• High-dose fludarabine is associated with significant toxicity in acute leukemias.
• Further long-term survival data are needed, but response correlates with survival in similar agents.